FDA: GSK's Avodart ads misleading

Share this article:
Consumer ads in support of GlaxoSmithKline's prostate drug Avodart overstate its efficacy and present misleading claims, the FDA said in a letter to the company.

The ad in question—a 60-second TV spot titled Planetarium—depicts artists working on planetary models, with one artist having to leave for the bathroom. Afterward, the actor recounts a conversation with his doctor: “Avodart is different because, over time, it actually shrinks the prostate, so I go less often. Other medicines, they don't treat the cause, because they don't shrink the prostate.” 

“The TV ad misleadingly suggests that Avodart is superior to other drug therapies when this has not been demonstrated by substantial evidence or substantial clinical experience,” DDMAC's Cynthia Collins, consumer safety officer, said in the letter, citing Merck's Proscar, another drug approved for the treatment of symptomatic benign prostatic hyperplasia.

FDA also took issue with a graphic showing a large planet and a small planet. “The visual of the planet shrinking in size represents a reduction in prostate volume that is much greater than the reduction actually achieved with Avodart therapy in clinical trials,” the letter said. “In fact, the approximately 20-25% reduction in volume corresponds to a difference in diameter of less than 10%.”

The untitled letter requested that GSK immediately cease dissemination of the ad, and submit a written response to the letter by March 4. 
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?